This article was originally published Aug. 13.
Helicos BioSciences said last week that it has placed a Helicos Genetic Analysis System at the Massachusetts General Hospital Cancer Center.
The instrument has been installed in the lab of Daniel Haber, who will explore the use of the system for use in characterizing circulating tumor cells, the company said.
Helicos did not disclose the financial terms of the agreement.
Patrice Milos, CSO of Helicos, said in a statement that the company expects "great synergies" for cancer research and diagnostics through the combination MGH's circulating tumor cell microchip and the Helicos system.
The placement follows the company's announcement earlier this month that it had sold one of its sequencers to an undisclosed biotechnology company in the Northeast (see In Sequence Aug. 4, 2009), and the publication last week of the first human genome to be sequenced on the system (see story, this issue).